Your Article Summary
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Journal of Neuro-Oncology, 07/02/09
Wen PY et al. - Although treatment was well-tolerated, neither gefitinib nor erlotinib appear to have significant activity against recurrent meningioma. The role of EGFR inhibitors in meningiomas is unclear. Evaluation of multi-targeted inhibitors and EGFR inhibitors in combination with other targeted molecular agents may be warranted.
Related Articles
A meningioma of the scalp that might have developed from a rudimentary meningocele
Clinical and Experimental Dermatology, 10/16/09
Relevance Score: 90%
Jugular fossa meningioma: Presentation and treatment options
ENT Journal, 10/21/09
Relevance Score: 89%
Diagnosis and Treatment of the Primary Malignant Meningioma in Mediastinum: A Case Report
Southern Medical Journal, 11/10/09
Relevance Score: 88%
Radiation-induced meningiomas: A shadow in the success story of childhood leukemia
Neuro-Oncology, 10/06/09
Relevance Score: 88%
Does protein expression predict recurrence of benign World Health Organization grade I meningioma
Human Pathology, 10/08/09
Relevance Score: 87%
Today in Neurologic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol
Cancer, 12/15/09
Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib
Critical Reviews in Oncology/Hematology, 12/15/09
Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas
Cancer Letters, 12/15/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
Cancer Chemotherapy and Pharmacology, 12/15/09
Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol
Cancer, 12/15/09
Dermatologic Infections in Cancer Patients Treated With Epidermal Growth Factor Receptor Inhibitor Therapy
Journal of the National Cancer Institute, 12/15/09

See Latest Articles